Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to $78.2 million.

  • Pharming's Accounts Payables rose 768.61% to $78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $78.2 million, marking a year-over-year increase of 768.61%. This contributed to the annual value of $66.6 million for FY2024, which is 815.82% down from last year.
  • Latest data reveals that Pharming reported Accounts Payables of $78.2 million as of Q3 2025, which was up 768.61% from $78.4 million recorded in Q2 2025.
  • In the past 5 years, Pharming's Accounts Payables ranged from a high of $78.4 million in Q2 2025 and a low of $42744.0 during Q3 2022
  • In the last 5 years, Pharming's Accounts Payables had a median value of $59.3 million in 2023 and averaged $51.6 million.
  • As far as peak fluctuations go, Pharming's Accounts Payables crashed by 9989.86% in 2022, and later skyrocketed by 14621293.28% in 2023.
  • Over the past 5 years, Pharming's Accounts Payables (Quarter) stood at $42868.0 in 2021, then soared by 126952.73% to $54.5 million in 2022, then surged by 33.16% to $72.5 million in 2023, then dropped by 8.16% to $66.6 million in 2024, then rose by 17.43% to $78.2 million in 2025.
  • Its Accounts Payables stands at $78.2 million for Q3 2025, versus $78.4 million for Q2 2025 and $68.7 million for Q1 2025.